A SIRT6 gene therapy trial in senior beagles hit its primary endpoint, lowering biological age and offering a test bed for human medicine.
Old dogs make surprisingly good stand-ins for aging humans. They live in our homes, eat roughly what we eat, breathe the same air and develop many of the same age-related conditions we do, just on a faster timeline. That’s part of why a UK biotech’s just-announced results from a beagle trial are getting attention well beyond the veterinary world.
Genflow Biosciences announced that its SLAB clinical trial, short for Sarcopenia and Longevity in Aged Beagles, has met its primary endpoint. The study tested the company’s SIRT6 centenarian gene therapy in dogs over the age of 10, and the treated animals showed a clear reduction in biological age compared with untreated controls, as measured by the GRIM DNA methylation clock, one of the more established tools researchers use to estimate how “old” tissue actually behaves, independent of a subject’s birthdate [1].
Borrowing biology from people who live past 100
Genflow’s approach centers on a specific variant of the SIRT6 gene, a version found more often in centenarians than in the general population, that appears to help protect cells against age-related decline. The company’s lead compound, GF-1002, delivers this centenarian variant directly, aiming to nudge aging tissue back toward a younger functional state rather than simply managing symptoms.
The trial itself was randomized and blinded, splitting 24 beagles over age 10 into four groups: two cohorts receiving naked DNA treatment at different doses, one group getting a single dose delivered via an AAV8 viral vector, and a saline control group. Hitting the primary endpoint builds on earlier signals the company had already flagged, including positive interim muscle data reported back in February and confirmation of sustained safety and efficacy at a three-month follow-up in April.
Beyond the headline result, Genflow says treated dogs showed improvement across several secondary functional and observable measures, too, though the company is holding the detailed breakdown for the Animal Longevity Summit (ALOS) in Toronto on 1–2 October. It’s a notable venue choice: ALOS bills itself as the first conference built entirely around animal longevity, and its speaker list, including researchers like Matt Kaeberlein, Vera Gorbunova and Aubrey de Grey, reads like a who’s who of the broader anti-aging research world. That overlap isn’t a coincidence. Companion animal trials are increasingly seen as a faster, more naturalistic proving ground for interventions that could eventually make their way to humans.
‘A real-world aging model’
“Meeting the primary endpoint in SLAB is a defining milestone for Genflow,” said Dr Eric Leire, the company’s CEO. “We set out to demonstrate that our centenarian SIRT6 naked DNA therapy could measurably address age-related decline in a real-world aging mode. This provides a powerful foundation for our partner discussions across animal health. We look forward to sharing the full dataset, including the critical methylation clock and muscle histology results, with the scientific and investment communities at the Animal Longevity Summit in October.”
That mention of partner discussions is worth noting. Genflow says it’s in active conversations with major global animal health companies about licensing and commercialization, which would be the fastest realistic route to market for a therapy like this: getting it into veterinary use for aging pets before the much longer road toward human regulatory approval.
Founded in 2020 and headquartered in the UK with R&D operations in Belgium, Genflow has built its pipeline entirely around age-related disease. Beyond the SIRT6 program in dogs, the company is exploring GF-1002 as a potential treatment for MASH, a common and stubborn form of liver disease, and developing a separate mRNA-based SIRT6 therapy, GF-1006, aimed at corneal disease and glaucoma.
Dogs won’t tell us everything about how a therapy like this behaves in people, and a successful trial in beagles is several steps removed from anything a human patient could access. However, sarcopenia, the muscle loss that comes with age, is one of the more universal and disabling parts of getting older, in dogs and people alike. A therapy that measurably slows it, even in a 24-dog trial, is the kind of early proof point the longevity field has been short on.
